A roughly 3-minute scientific video
Introduce the disease, treatment approach and available evidence before a meeting or education session, with a script tailored to your audience.
Patient education · Physician education · Investor and partner understanding
How a personalized mRNA vaccine turns tumor mutations into immune targets.
Explain what makes a cancer vaccine personal to the patient. Follow target selection, mRNA delivery and T-cell recognition, then examine the evidence for V940 with pembrolizumab after melanoma surgery.
How Intismeran autogene (V940) works
Intismeran autogene (V940, also called mRNA-4157) is an investigational individualized neoantigen therapy. It encodes selected targets based on the mutational signature of a patient's tumor. This example follows the vaccine and the separate contribution of pembrolizumab in melanoma after surgery.
- Select and encode. Tumor-specific changes inform the individualized mRNA design.
- Deliver, translate and present. Antigen-containing proteins are produced and processed so peptides can be presented to the immune system.
- Prime and recognize. Responsive T cells expand and can recognize matching peptide–MHC on a target cell.
- Block an inhibitory interaction. Pembrolizumab binds PD-1 and blocks ligand engagement; this is distinct from the vaccine's antigen instructions.
The full 1-minute-56-second film has a light scientific score and English captions. The interactive experience includes the complete eight-stage journey and close molecular studies using experimental structures.
Eight stages from tumor sequence to immune response
A labeled mechanism figure connects individualized target selection, RNA delivery, translation, antigen presentation, T-cell priming, PD-1 blockade, recognition and a possible cellular response.
Recurrence-free survival after melanoma surgery
The clinical figure shows the KEYNOTE-942 Phase 2b recurrence-free survival hazard ratio with its confidence interval, and separately summarizes the Phase 3 INTerpath-001 topline.
The evidence brief identifies each study population, reported endpoint and source date. Numerical Phase 3 effect sizes were not disclosed in the cited August 2026 release; overall survival follow-up continues.
Scientific sources and representation limits
The mechanism summary below the film is based on the primary sources linked here. The source notes describe how those references relate to the visuals.
- KEYNOTE-942 five-year sponsor update, 20 January 2026
- INTerpath-001 Phase 3 topline, 19 August 2026
- Representative TCR–peptide–MHC structure, PDB 7PHR
- Human ribosome structure, PDB 8JDM
- Pembrolizumab Fab–PD-1 structure, PDB 5GGS
- Figure sources and representation notes
Intismeran remains investigational. The scene uses representative structural coordinates, not a measured V940 patient-specific recognition complex. Motion, cellular context and target-cell responses are illustrative. Clinical trial endpoints and reported effects are kept distinct from animated cell death. Pembrolizumab has serious immune-mediated risks; this example is not a complete safety presentation.
How this example could support a program
A content foundation for an education program explaining individualized cancer therapies to patients or physicians, or for a separate partner communication program. Tailored materials can connect the scientific rationale with the clinical question being studied and explain the distinct contributions of the vaccine and accompanying treatment.
An interactive website
Give people a resource to revisit and share after a study discussion, physician presentation or partnering meeting, with mechanism steps and supporting references available.
Scientific report and literature review
A focused, referenced review of the mechanism, clinical findings and open questions, including two publication-quality figures. Reuse the figures in presentations, with captions, references and editable SVG, vector PDF and PNG exports.
Who needs to understand your medicine next?
Tell us about the treatment, audience and milestone. We will scope the program objectives, scientific content, formats, review process and evaluation needs, whether for patient or physician education, or a separate investor and partner communication program.
Discuss your education needs ↗